BioLife Solutions’ (BLFS) Buy Rating Reaffirmed at Maxim Group

Maxim Group restated their buy rating on shares of BioLife Solutions, Inc. (NASDAQ:BLFS) in a research note issued to investors on Thursday morning. Maxim Group currently has a $7.00 price objective on the medical equipment provider’s stock.

“With the first CAR-T therapies from Gilead (Kite’s Yescarta) (GILD – $79.89 – Hold) and Novartis (Kymriah) (NVS – $81.37 – NR) now on the market, the focus has shifted towards manufacturing. Can CAR-T be made at scale? As the launches of Yescarta and Kymriah continue we will find out.”,” the firm’s analyst commented.

Separately, Janney Montgomery Scott raised BioLife Solutions from a neutral rating to a buy rating and boosted their price target for the company from $2.62 to $5.00 in a research note on Wednesday, July 5th.

BioLife Solutions (NASDAQ BLFS) traded down 6.88% during midday trading on Thursday, hitting $5.41. 148,624 shares of the company traded hands. The company’s market cap is $71.56 million. The stock has a 50 day moving average price of $5.54 and a 200-day moving average price of $3.60. BioLife Solutions has a 12-month low of $1.43 and a 12-month high of $7.53.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 10th. The medical equipment provider reported ($0.06) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The business had revenue of $2.56 million during the quarter, compared to analysts’ expectations of $2.40 million. BioLife Solutions had a negative return on equity of 64.98% and a negative net margin of 63.71%. Analysts expect that BioLife Solutions will post ($0.24) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/10/30/biolife-solutions-blfs-buy-rating-reaffirmed-at-maxim-group.html.

About BioLife Solutions

BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.

What are top analysts saying about BioLife Solutions Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioLife Solutions Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit